Stay updated with breaking news from Philippe Dro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LimmaTech has leveraged a novel technology platform to produce a pipeline of vaccines against multi-resistant bacterial infections that present global health threatsSCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threate...
/PRNewswire/ -- GlycoEra AG announced today key appointments of biotech industry leaders to its Board of Directors, including Georges Gemayel, Ph.D., as Chair,...
07.05.2021 15:30 Swiss start-ups expand globally at an early stage and and their success draws international investors’ attention to Switzerland as a start-up location. Dear reader International orientation is one of the strengths of the Swiss economy. Accordingly, it is a matter of course for Swiss start-ups to expand globally with the help of their first major investment. The number of such start-ups is high: this week alone we reported on five companies that after completion of an early stage round are now addressing global markets. The range is wide, from cybersecurity company Exeon A...
DGAP-News: Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman 02.02.2021 / 09:30 PRESS RELEASE - Dr. Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience - Successful serial entrepreneur with track record of growing companies, notably for Themis and Glycovaxyn - Joins at a key juncture in Scenic Biotech's strategic growth, building its pipeline of genetic modifier drug candidates Amsterdam, The Netherlands, 2 February, 2021 - Sceni...
Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience Successful serial entrepreneur with track record of growing companies, notably for Themis and GlycoVaxyn Joins at a key juncture in Scenic Biotech’s strategic growth, building its pipeline of genetic modifier drug candidates AMSTERDAM, The Netherlands, February 02, 2021 / B3C newswire / --Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today a...